Conformetrix to present at ELRIG Drug Discovery 2012

Company to discuss conformational insights

Manchester, UK, September 3 2012 – Conformetrix Ltd, a leader in optimising drug discovery and design, will be presenting at ELRIG Drug Discovery 20121 on September 6 2012. The presentation, 'The application of ligand conformational preferences in drug discovery', will discuss how the tuning of conformational preferences can be used to optimise the potency of drug candidates.

As well as insights from Conformetrix's proprietary preclinical drug discovery programmes, Senior Medicinal Chemist Barrie Martin will discuss projects in which the dynamic 3D-structures of two drug molecules were solved.

Conformetrix’s NMR technology determines accurate three-dimensional structures - or conformations - of drug molecules in their bioactive states. This is achieved without the need for traditional structural information regarding the protein target of each drug and provides researchers with valuable information on how development-stage compounds are likely to interact with their targets. This new information should improve the efficiency and quality of the lead identification, lead optimisation and candidate selection stages of drug discovery programmes.

1 ELRIG/SLAS Drug Discovery 2012, September 5-6 2012, Manchester, UK, www.elrig.org

1 ELRIG/SLAS Drug Discovery 2012, September 5-6 2012, Manchester, UK, www.elrig.org